Skip to main content
Clinical Trials/NCT07344467
NCT07344467
Recruiting
Not Applicable

Effect of Oral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery: A Prospective, Randomized Controlled Trial

Tanta University1 site in 1 country105 target enrollmentStarted: January 17, 2026Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
105
Locations
1
Primary Endpoint
Degree of pain

Overview

Brief Summary

This study aims to compare the efficacy of using Melatonin versus Pregabalin on postoperative pain and anxiety after spine surgeries.

Detailed Description

Spine surgery is one of the most common procedures performed every day which is associated with intense pain in the postoperative period, mostly in the first few days after surgery. Effective pain management leads to improved functional outcomes, early ambulation, prevention of chronic pain and early discharge.

Melatonin is neurohormone mainly secreted from the pineal gland by the suprachiasmatic nucleus. This neurohormone possesses a circadian secretion pattern and regulates the biological clock; it also offers antiemetic, analgesic, and anxiolytic effects.

Pregabalin is a structural analogue of gamma-aminobutyric acid that acts as a potent ligand for alpha 2-delta subunits of the voltage-gated calcium channels in the nervous system. Such action results in a reduction in the depolarization-induced influx of calcium, hence a reduction in the release of excitatory neurotransmitters including glutamate, noradrenaline, dopamine, and serotonin.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
21 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients aged 21-60 years old.
  • Both sexes.
  • Patients of American Society of Anesthesiologists (ASA) physical status I \& II.
  • Undergoing elective spine surgery.

Exclusion Criteria

  • Patient refusal.
  • History of allergic reactions to melatonin or pregabalin.
  • Patients with cardiovascular disease (ischemic heart disease, Heart Failure, Arrythmia, Heart Block).
  • Patients with kidney disease with (plasma creatinine level \> 1.5mg/dl).
  • Patients with liver disease with (aspartate transaminase, alanine transaminase, and bilirubin levels more than twice the upper limit of normal).
  • Psychological and cognitive disorders; dementia; major depression.
  • Circadian rhythm disorders such as chronic fatigue syndrome and drowsiness.

Arms & Interventions

Group C (Control Group)

Placebo Comparator

Patients will be receive one oral placebo capsule the evening before surgery, one oral placebo capsule 2 hours prior to surgery, and one oral placebo capsule in the morning and one in the evening for 3 consecutive days postoperatively.

Intervention: Placebo capsule (Other)

Group M (Melatonin Group)

Experimental

Participants will receive one 5 mg oral melatonin capsule the evening before surgery, one 5 mg oral melatonin capsule 2 hours prior to surgery, and one oral placebo capsule in the morning, and one 5 mg oral melatonin capsule in the evening, daily for 3 consecutive days postoperatively.

Intervention: Melatonin capsule (Drug)

Group P (Pregabalin Group)

Experimental

Participants will receive one 75 mg oral pregabalin capsule the evening before surgery, one 75 mg oral pregabalin capsule 2 hours prior to surgery, and one 75 mg oral pregabalin capsule in the morning, and another in the evening, daily for 3 consecutive days postoperatively.

Intervention: Pregabalin capsule (Drug)

Outcomes

Primary Outcomes

Degree of pain

Time Frame: 3 days postoperatively

Postoperative pain will be assessed using the Visual Analogue Scale (VAS) at the following time points: upon arrival to the Post-Anesthesia Care Unit (PACU), and at 1, 2, 4, 6, 8, 12, and 24 hours, as well as at 12 and 24 hours on postoperative days 2 and 3.

Secondary Outcomes

  • Incidence of postoperative anxiety(3 days postoperatively)
  • Postoperative analgesic consumption(3 days postoperatively)
  • Postoperative sleep quality(3 days postoperatively)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ahmed Hamdy Said Ayad

Assistant lecturer of Anesthesia, Surgical Intensive Care and Pain Medicine, Tanta University, Tanta, Egypt.

Tanta University

Study Sites (1)

Loading locations...

Similar Trials